Patient Advocacy Groups Take In Millions From Drugmakers. Is There A Payback?
Kaiser Health News launches “Pre$cription for Power,” a groundbreaking database to expose Big Pharma’s ties to patient groups.
Liquid Gold: Pain Doctors Soak Up Profits By Screening Urine For Drugs
With the nation’s opioid crisis, urine testing has become a booming business and is especially lucrative for doctors who operate their own labs, a Kaiser Health News investigation finds. And dozens of practitioners have earned “the lion’s share” of their Medicare income exclusively from urine drug screens.
Right After Trump Blamed High Drug Prices On Campaign Cash, Drugmakers Gave More
At a political rally in March, President Donald Trump said drug prices are “outrageous” and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
Follow The Money: Drugmakers Deploy Political Cash As Prices And Anger Mount
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
With Drug Costs In Crosshairs, Health Firms Gave Generously To Trump’s Inauguration
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Enfermos… ¿y en bancarrota? Consumidores gastarán más en drogas en 2017
En 2017, muchos más planes de salud en los mercados de seguros requerirán que los consumidores paguen una sustancial parte del costo de los medicamentos más caros, dicen, para disuadir a pacientes muy enfermos de elegir sus planes.
Need Pricey Drugs From An Obamacare Plan? You’ll Shoulder More Of The Cost
A Kaiser Health News analysis finds that the portion of federal marketplace plans requiring people to pay a third or more of the cost of specialty drugs have jumped from 37 to 63 percent since 2014.
